Showing results (281-290 of 831) with videos related to
Sort By:
Pageof 84
Blood|October 12, 2023
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trialDespoina Papazoglou, Xin Victoria Wang, Tait D Shanafelt, et al.Molecular Cancer Therapeutics|August 13, 2015
Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKsShuntaro Tsukamoto, Yuhui Huang, Motofumi Kumazoe, et al.Cancer|April 28, 2011
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinibAlfonso Quintás-Cardama, Hagop Kantarjian, Jianqin Shan, et al.Cancer|October 26, 2007
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapiesGautam Borthakur, E Lin, Stefan Faderl, et al.Leukemia & Lymphoma|October 30, 2009
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapyEllen J Schlette, Joan Admirand, William Wierda, et al.Autophagy|August 24, 2010
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagyYue Wei, Tapan Kadia, Weigang Tong, et al.Cancer|July 12, 2007
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinibJorge Cortes, Elias Jabbour, George Q Daley, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
Phase I study of oral topotecan in hematological malignanciesMiloslav Beran, Susan O'Brien, Deborah A Thomas, et al.Blood|June 21, 2003
Rituximab in relapsed or refractory hairy cell leukemiaDeborah A Thomas, Susan O'Brien, Carlos Bueso-Ramos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Elias Jabbour, Hagop M Kantarjian, Susan O'Brien, et al.Pageof 84